Kinnevik Ab (publ) is an investment fund managing more than $74.5 billion ran by Samuel Sjostrom. There are currently 2 companies in Mr. Sjostrom’s portfolio. The largest investments include Recursion Pharmaceuticals, Inc. and Babylon Holdings Ltd, together worth $74.5 billion.
As of 7th April 2023, Kinnevik Ab (publ)’s top holding is 7,653,061 shares of Recursion Pharmaceuticals, Inc. currently worth over $51 billion and making up 68.5% of the portfolio value.
In addition, the fund holds 4,617,340 shares of Babylon Holdings Ltd worth $23.5 billion.
Currently, Kinnevik Ab (publ)'s portfolio is worth at least $74.5 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Kinnevik Ab (publ) office and employees reside in Stockholm, Sweden. According to the last 13-F report filed with the SEC, Samuel Sjostrom serves as the Chief Financial Officer at Kinnevik Ab (publ).
There are companies that Kinnevik Ab (publ) is getting rid of from its portfolio.
Kinnevik Ab (publ) closed its position in Teladoc Health Inc on 14th April 2023.
It sold the previously owned 3,683,668 shares for $87.1 billion.
The two most similar investment funds to Kinnevik Ab (publ) are Park Avenue Institutional Advisers and Rhumbline Advisers. They manage $74.6 billion and $74.4 billion respectively.
These positions were updated on April 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Teladoc Health Inc |
Closed
3,683,668
|
$87,118,748,000 | |
| Recursion Pharmaceuticals, Inc. |
No change
7,653,061
|
$51,045,917,000 | 68.47% |
| Babylon Holdings Ltd |
No change
4,617,340
|
$23,502,261,000 | 31.53% |
| No transactions found | |||
| Showing first 500 out of 3 holdings | |||